Databasing for Dollars
Genome Therapeutics has now signed its third data base deal, virtually completing its metamorphosis from a positional cloner into a data base provider. The new mantra for platform companies: if you create information, sell information. GTC finds selling subscriptions easier and more profitable than selling research deals since the number of potential subscribers is, unlike the number of potential deal partners, virtually unlimited.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.